A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707 in Healthy Young Adult and Elderly Subjects
Latest Information Update: 28 Aug 2023
At a glance
- Drugs SHR-1707 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 20 Jul 2023 Results of pooled analysis from NCT04973189, NCT04745104 safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single intravenous dose of SHR-1707 in healthy adult subjects assessing presented at the Alzheimer's Association International Conference 2023.
- 11 Jul 2022 Status changed from recruiting to completed.
- 12 Oct 2021 Planned End Date changed from 1 Dec 2022 to 1 May 2022.